February 1, 2021
Daiichi Sankyo’s April-December group sales dropped 2.4% year on year due to the negative growth of its mainstay products at home, despite the bullish performance of the anticancer agent Enhertu (trastuzumab deruxtecan) and the anticoagulant Lixiana (edoxaban) in overseas markets,...read more